Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care

Current Hypertension Reports

Volumn 7, Issue 6, 2005, Pages 439-449

  Borzecki, Ann M ^a   Berlowitz, Dan R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; LISINOPRIL; LOSARTAN; METOPROLOL; PLACEBO; RESERPINE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE CONTROL; DRUG CHOICE; DRUG COST; DRUG INDICATION; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; META ANALYSIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES;

EID: 31344456764     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0039-7     Document Type: Review

References (74)

1. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
2. Berlowitz DP, Ash AS, Hickey EC, et al.: Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003, 26:355-359.
3. Godley PJ, Maue SK, Farrelly EW, Frech F: The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005, 11:206-210.
4. Geiss LS, Rolka DB, Engelgau MM: Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 2002, 22:42-48.
5. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
6. DeStefano F, Ford ES, Newman J, et al.: Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993, 3:27-34.
7. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26(Suppl 1): S80-S82.
8. US Renal Data System: USRDS 2004 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2005. Available at: http://www.usrds.org
9. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
10. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
11. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134-147.
12. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
13. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2):B54-B64.
15. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
16. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
17. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
18. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
19. Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555-1565.
20. Joint National Committee: The sixth report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure Arch Intern Med 1997, 157:2413-2446.
21. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
22. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
23. 2004 Canadian Hypertension Education Program Recommendations: Executive Summary. http://www.hypertension.ca/Documentation/CHEP2004_exec_summary.pdf. Accessed June 24, 2005.
24. Williams B, Poulter NR, Brown MJ, et al.: British Hypertension Society guidelines for hypertension management 2004 (BHSIV): summary. BMJ 2004, 328:634-640.
25. Office of Performance and Quality: VHA/DOD Clinical Practice Guideline for Diagnosis and Managment of Hypertension in the Primary Care Setting. http://www.oqp.med.va.gov/cpg/HTN/HTN_Base.htm. Accessed June 1, 2005.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
27. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601-606.
28. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
29. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
30. Pahor M, Psaty BM, Alderman MH, et al.: Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000, 23:888-892.
31. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
33. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283:1967-1975.
34. Barzilay JI, Davis BR, Bettencourt J, et al.: Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich) 2004, 6:116-125.
35. Whelton PK, Barzilay J, Cushman WC, et al.: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401-1409.
36. Rahman M, Pressel S, Davis BR, et al.: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936-946.
37. Turnbull F, Neal B, Algert C, et al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
38. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
39. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998,21:597-603.
40. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964.
41. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
42. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
43. Borzecki AM, Wong AT, Hickey EC, et al.: Hypertension control: How well are we doing? Arch Intern Med 2003, 163:2705-2711.
44. Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-405.
45. Huggett RJ, Scott EM, Gilbey SG, et al.: Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003, 108:3097-3101.
46. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
47. Sarafidis PA, Lasaridis AN, Nilsson PM, et al.: Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004, 22:1769-1777.
48. Borzecki AM, Oliveria SA, Berlowitz DR: Barriers to hypertension control. Am Heart J 2005, 149:785-794.
49. Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339(27):1957-1963.
50. Phillips LS, Branch WT, Cook CB, et al.: Clinical inertia. Ann Intern Med 2001, 135:825-834.
51. Oliveria SA, Lapuerta P, McCarthy ED, et al.: Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413-420.
52. Pellegrini F, Belfiglio M, De Berardis G, et al.: Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group-quality of care and outcomes in type 2 diabetes. Arch Intern Med 2003, 163:473-480.
53. Grimshaw JM, Shirran L, Thomas R, et al.: Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001, 39(8 Suppl 2):112-1145.
54. Oxman AD, Thomson MA, Davis DA, Haynes RB: No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995, 153:1423-1431.
55. New JP, Mason JM, Freemantle N, et al.: Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care 2003, 26:2250-2255.
56. Denver EA, Barnard M, Woolfson RG, Earle KA: Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care 2003, 26:2256-2260.
57. Taylor CB, Miller NH, Reilly KR, et al.: Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care 2003, 26:1058-1063.
58. Krein SL, Klamerus ML, Vijan S, et al.: Case management for patients with poorly controlled diabetes: a randomized trial. Am J Med 2004, 116:732-739.
59. Grol R: Personal paper. Beliefs and evidence in changing clinical practice. BMJ 1997, 315:418-421.
60. Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the quality gap: a critical analysis of quality improvement strategies. Volume 1: Series overview and methodology. AHRQ Publication No. 04-0051-1. In Rockville, MD: Agency for Healthcare Research and Quality, 2004.
61. Shojania KG, Ranjii SR, Shaw LK, et al.: Closing the quality gap: a critical analysis of quality improvement strategies. Volume 2: Diabetes mellitus care. AHRQ Publication No. 04-0051-2. In Rockville, MD: Agency for Healthcare Research and Quality, 2004.
62. Walsh J, McDonald KM, Shojania KG, et al.: Closing the quality gap: a critical analysis of quality improvement strategies. Volume 3: Hypertension care. AHRQ Publication No. 04-0051-3. In Rockville, MD: Agency for Healthcare Research and Quality; 2005.
63. Chobanian AV. Control of hypertension - an important national priority. N Engl J Med 2001, 345:534-535.
64. National Diabetes Education Program: Be Smart About Your Heart. Control the ABCs of Diabetes. http://ndep.nih.gov/campaigns/BeSmart/BeSmart-index.htm. Accessed June 29, 2005.
65. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993, 342:1317-1322.
66. Haynes RB, McDonald H, Garg AX, Montague P: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002, 2:CDO00011.
67. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
68. Niskanen L, Hedner T, Hansson L, et al.: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091-2096.
69. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
70. Smith NL, Savage PJ, Heckbert SR, et al.: Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc 2002, 50:416-423.
71. Smith NL, Chen L, Au DH, et al.: Cardiovascular risk factor control among veterans with diabetes: the ambulatory care quality improvement project. Diabetes Care 2004, 27(Suppl 2):B33-B38.
72. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718-723.
73. Singer GM, Izhar M, Black HR: Guidelines for hypertension: Are quality-assurance measures on target? Hypertension 2004, 43:198-202.
74. Duggirala MK, Cuddihy RM, Cuddihy MT, et al.: Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005, 18:833-838.